Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 11/20 | 0.51 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | APAF1 | O14727 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.42 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.42 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30737737 | 1.00 | S1PR3 (0.51) | S1PR3ARCYP11B1CYP11B2MEN1 | |
| SCHEMBL996704 | 0.85 | MRGPRX4 (0.56) | S1PR3MEN1KMT2AMRGPRX4TSHR | |
| SCHEMBL7662707 | 0.85 | VNN1 (0.45) | S1PR3CYP11B1CYP11B2MEN1APAF1 | |
| SCHEMBL16961084 | 0.84 | S1PR3 (0.47) | S1PR3ARMRGPRX4S1PR1S1PR2 | |
| SCHEMBL2767509 | 0.83 | S1PR3 (0.50) | S1PR3ARCYP11B2MRGPRX4S1PR1 | |
| SCHEMBL1275282 | 0.83 | S1PR3 (0.54) | S1PR3S1PR1S1PR2S1PR4 | |
| SCHEMBL2620548 | 0.81 | CYP2A6 (0.43) | S1PR3KMT2ACYP2A6ALDH1A1 | |
| SCHEMBL10412463 | 0.81 | CYP2A6 (0.43) | S1PR3KMT2ACYP2A6TSHRALDH1A1 | |
| SCHEMBL18724341 | 0.81 | S1PR3 (0.44) | S1PR3ARMRGPRX4S1PR1S1PR2 | |
| SCHEMBL6970906 | 0.81 | PKM (0.46) | CYP11B1CYP11B2MEN1APAF1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119019281-A | Preparation method of 4-acetyl-2-methylbenzonitrile | 黑龙江立科新材料有限公司 | 2024-11-26 | — | — | CN | claimed |
| CN-113512007-A | Synthesis of flurarana | 江苏君若药业有限公司 | 2021-10-19 | — | — | CN | claimed |
| CN-109553528-A | A kind of synthetic method of 2- methyl -4- acetylbenzoic acid methyl esters | 荆门医药工业技术研究院 | 2019-04-02 | — | — | CN | claimed |
| CN-120843616-A | Biocatalysis method for synthesizing 4-acetyl-2-methylbenzoic acid based on 4-acetyl-2-methylbenzonitrile | 常州大学 | 2025-10-28 | — | — | CN | disclosed |
| CN-120843616-A | Biocatalysis method for synthesizing 4-acetyl-2-methylbenzoic acid based on 4-acetyl-2-methylbenzonitrile | 常州大学 | 2025-10-28 | — | — | CN | disclosed |
| CN-120383525-A | Preparation method of 2-methyl-4-acetyl benzoic acid | 潍坊市海欣药业有限公司 | 2025-07-29 | — | — | CN | disclosed |
| CN-119751370-A | Preparation method of fluororalrana | 河北威远药业有限公司 | 2025-04-04 | — | — | CN | disclosed |
| US-20250091998-A1 | A PROCESS FOR THE PREPARATION OF CARBAMOYL BENZAMIDE PHENYL ISOXAZOLINE CLASS DRUG/S AND ITS INTERMEDIATES | ZENFOLD SUSTAINABLE TECHNOLOGIES PRIVATE LIMITED (IN) | 2025-03-20 | — | — | US | disclosed |
| CN-119019281-A | Preparation method of 4-acetyl-2-methylbenzonitrile | 黑龙江立科新材料有限公司 | 2024-11-26 | — | — | CN | disclosed |
| CN-119019281-A | Preparation method of 4-acetyl-2-methylbenzonitrile | 黑龙江立科新材料有限公司 | 2024-11-26 | — | — | CN | disclosed |
| CN-119019281-A | Preparation method of 4-acetyl-2-methylbenzonitrile | 黑龙江立科新材料有限公司 | 2024-11-26 | — | — | CN | disclosed |
| EP-2960333-B1 | COMPOSITION FOR INHIBITING GENE EXPRESSION AND USES THEREOF | IDERA PHARMACEUTICALS INC (US) | 2017-10-04 | — | — | EP | disclosed |
| EP-1781661-B1 | VASOPRESSIN V1A ANTAGONISTS | VANTIA LTD (GB) | 2017-06-07 | — | — | EP | disclosed |
| EP-2539335-B1 | PROCESS FOR THE PREPARATION OF ISOXAZOLINE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2016-12-21 | — | — | EP | disclosed |
| EP-2539335-B1 | PROCESS FOR THE PREPARATION OF ISOXAZOLINE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2016-12-21 | — | — | EP | disclosed |
| US-20140206633-A1 | PROCESS FOR THE PREPARATION OF ISOXAZOLINE DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140206633-A1 | PROCESS FOR THE PREPARATION OF ISOXAZOLINE DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140206633-A1 | PROCESS FOR THE PREPARATION OF ISOXAZOLINE DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2014-07-24 | — | — | US | disclosed |
| EP-2539335-A1 | PROCESS FOR THE PREPARATION OF ISOXAZOLINE DERIVATIVES | Syngenta Participations AG (CH) | 2013-01-02 | — | — | EP | disclosed |
| WO-2011104089-A1 | PROCESS FOR THE PREPARATION OF ISOXAZOLINE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2011-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250091998-A1 | A PROCESS FOR THE PREPARATION OF CARBAMOYL BENZAMIDE PHENYL ISOXAZOLINE CLASS DRUG/S AND ITS INTERMEDIATES | CYP3A7, CYP1A2, CYP1B1 | S1PR3 2978/4885AR 331/4885CYP11B1 226/4885 |
| US-20140206633-A1 | PROCESS FOR THE PREPARATION OF ISOXAZOLINE DERIVATIVES | CYP1A2, CHRM1, CYP1A1 | S1PR3 2497/4885AR 1759/4885CYP11B1 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.